ETON Eton Pharmaceutcials, Inc.

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical product using the U.S. Food and Drug Administration's 505(b)(2) regulatory pathway. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company is developing DS-300, an injectable nutrition product candidate; EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-103, an oral liquid product candidate; DS-100, an injectable product candidate for use in pain management; DS-200, an injectable parenteral nutrition product candidate; ET-101, an oral liquid product for use in seizure control; ET-102, an oral liquid product for use as a muscle relaxant; and CT-100, a synthetic corticotropin therapeutic candidate that mimics the amino acid chain of H.P. Acthar Gel. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

$4.22
As of 11/26/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  11/13/2018
Outstanding shares:  24,606,175
Average volume:  621,754
Market cap:   $106,298,676
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    29772L108
ISIN:        US29772L1089
Sedol:      
Valuation   (See tab for details)
PE ratio:   -9.72
PB ratio:   6.64
PS ratio:   6.72
Return on equity:   -68.21%
Net income %:   -67.52%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy